AI assistant
Sending…
Moderna, Inc. — Director's Dealing 2019
Nov 22, 2019
30610_dirs_2019-11-22_ab6f455a-883d-4542-8d53-7eb64dbeaa14.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2019-11-20
Reporting Person: HUTT PETER BARTON (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-11-20 | Common Stock | M | 200000 | $.04 | Acquired | 203924 | Direct |
| 2019-11-20 | Common Stock | S | 200000 | $20.18 | Disposed | 3924 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-11-20 | Stock Option (Right to Buy) | $.04 | M | 200000 | Disposed | 2022-03-27 | Common Stock (200000) | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. The shares sold in multiple transactions at prices ranging from $20.00 to $20.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F2: This option is fully vested and exercisable.
More from Moderna, Inc.
Declaration of Voting Results & Voting Rights Announcements
2026
May 11
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Feb 25
Regulatory Filings
2026
Feb 23
Annual Report
2026
Feb 20
Director's Dealing
2026
Feb 13
Director's Dealing
2026
Feb 13